Humanized-VH/VHH that inhibit HCV replication by interfering with the virus helicase activity

Journal of Virological Methods

Volumn 194, Issue 1-2, 2013, Pages 289-299

  Phalaphol, Aninthita ^a   Thueng in, Kanyarat ^b   Thanongsaksrikul, Jeeraphong ^c   Poungpair, Ornnuthchar ^a   Bangphoomi, Kunan ^b   Sookrung, Nitat ^a   Srimanote, Potjanee ^c   Chaicumpa, Wanpen ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b KASETSART UNIVERSITY   (Thailand)

^c THAMMASAT UNIVERSITY   (Thailand)

Author keywords

Cell penetrable antibody (transbody); Epitope; Hepatitis C virus (HCV) helicase; Humanized camel VH VHH; Virus neutralization assay

Indexed keywords

EPITOPE; HELICASE; NONSTRUCTURAL PROTEIN 2; PENETRATIN; VIRUS RNA; ANTIVIRUS AGENT; COMPLEMENTARY DNA; HEPATITIS C ANTIBODY; NS3 PROTEIN, HEPATITIS C VIRUS; RNA; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; GENOTYPE; HEPATITIS C VIRUS; MOLECULAR DOCKING; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS NEUTRALIZATION; VIRUS REPLICATION; ANIMAL; C-TERMINAL AT TWO-THIRDS OF THE NON-STRUCTURAL NS3 PROTEIN OF HEPATITIS C VIRUS; CAMEL; CELL LINE; CELL PENETRABLE ANTIBODY (TRANSBODY); CELL SURFACE DISPLAY; DRUG ANTAGONISM; DRUG EFFECT; FLUORESCENT RESONANCE ENERGY TRANSFER; FRET; GENETICS; HCV; HEPATITIS C VIRUS (HCV) HELICASE; HUMAN; HUMANIZED-CAMEL VH/V(H)H; IMMUNOLOGY; ISOLATION AND PURIFICATION; NS3-C; OD; OPTICAL DENSITY; PCR; PHYSIOLOGY; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RT-PCR; V(H)H; VARIABLE HEAVY CHAIN DOMAIN; VARIABLE HEAVY CHAIN DOMAIN OF THE HEAVY CHAIN ANTIBODY; VH; VIRUS NEUTRALIZATION ASSAY;

C-TERMINAL AT TWO-THIRDS OF THE NON-STRUCTURAL NS3 PROTEIN OF HEPATITIS C VIRUS; CDNA; CELL PENETRABLE ANTIBODY (TRANSBODY); COMPLEMENTARY DEOXYRIBONUCLEIC ACID; EPITOPE; FLUORESCENT RESONANCE ENERGY TRANSFER; FRET; HCV; HEPATITIS C VIRUS; HEPATITIS C VIRUS (HCV) HELICASE; HUMANIZED-CAMEL VH/V(H)H; NS3-C; OD; OPTICAL DENSITY; PCR; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RIBONUCLEIC ACID; RNA; RT-PCR; V(H)H; VARIABLE HEAVY CHAIN DOMAIN; VARIABLE HEAVY CHAIN DOMAIN OF THE HEAVY CHAIN ANTIBODY; VH; VIRUS NEUTRALIZATION ASSAY;

ANIMALS; ANTIVIRAL AGENTS; CAMELS; CELL LINE; CELL SURFACE DISPLAY TECHNIQUES; ESCHERICHIA COLI; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HUMANS; SINGLE-CHAIN ANTIBODIES; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84884911363     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2013.08.032     Document Type: Article

References (36)

1. Carreño V., Pardo M., López-Alcorocho J.M., Rodríguez-Iñigo E., Bartolomé J., Castillo I. Detection of hepatitis C virus (HCV) RNA in the liver of healthy, anti-HCV antibody-positive, serum HCV RNA-negative patients with normal alanine aminotransferase levels. J. Infect. Dis. 2006, 194:53-60.
2. HH) that bound specifically to Naja kaouthia phospholipase A2 and neutralized the enzymatic activity. Toxins 2012, 4:554-567.
3. Feld J.J., Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005, 436:967-972.
4. Frick D.N., Rypma R.S., Lam A.M., Frenz C.M. Electrostatic analysis of the hepatitis C virus NS3 helicase reveals both active and allosteric site locations. Nucleic Acids Res. 2004, 32:5519-5528.
5. Frick D.N. The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target. Curr. Issues Mol. Biol. 2007, 9:1-20.
6. Hamers-Casterman C., Atarhouch T., Muyldermans S., Robinson G., Hamers C., Songa E.B., Bendahman N., Hamers R. Naturally occurring antibodies devoid of light chains. Nature 1993, 363:446-448.
7. Han Q., Xu C., Wu C., Zhu W., Yang R., Chen X. Compensatory mutations in NS3 and NS5A proteins enhance the virus production capability of hepatitis C reporter virus. Virus Res. 2009, 145(1):63-73.
8. Accessed on February 12th, 2013. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm256328.htm.
9. Accessed on 12.02.13. http://www.fda.gov/NewsEvents/Newsroom/Press?Announcements/ucm255390.htm.
10. Jennings T.A., Mackintosh S.G., Harrison M.K., Sikora D., Sikora B., Dave B., Tackett A.J., Cameron C.E., Raney K.D. NS3 helicase from the hepatitis C virus can function as a monomer or oligomer depending on enzyme and substrate concentrations. J. Biol. Chem. 2009, 284:4806-4814.
11. Jin L., Peterson D.L. Expression, isolation, and characterization of the hepatitis C virus ATPase/RNA helicase. Arch. Biochem. Biophys. 1995, 323:47-53.
12. Jones D.M., McLauchlan.J. Hepatitis C virus: assembly and release of virus particles. J. Biol. Chem. 2010, 23(285 (30)):22733-22739.
13. Kim D.W., Gwack Y., Han J.H., Choe J. Towards defining a minimal functional domain for NTPase and RNA helicase activities of hepatitis C virus NS3 protein. Virus Res. 1997, 49:17-25.
14. Kota S., Scampavia L., Spicer T., Beeler A.B., Takahashi V., Snyder J.K., Porco J.A., Hodder P., Strosberg A.D. A time-resolved fluorescence-resonance energy transfer assay for identifying inhibitors of hepatitis C virus core dimerization. Assay Drug Dev. Technol. 2010, 8:96-105.
15. Krawczyk M., Stankiewicz-Drogon A., Haenni A.L., Boguszewska-Chachulska A. Fluorometric assay of hepatitis C virus NS3 helicase activity. Methods Mol. Biol. 2010, 587:211-221.
16. Krishnan S.M., Dixit N.M. Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy. PLoS Comput. Biol. 2011, 7:e1001072.
17. Kwong A.D., Rao B.G., Jeang K.T. Viral and cellular RNA helicases as antiviral targets. Nat. Rev. Drug Discov. 2005, 4:845-853.
18. Lam A.M., Keeney D., Frick D.N. Two novel conserved motifs in the hepatitis C virus NS3 protein critical for helicase action. J. Biol. Chem. 2003, 278:44514-44524.
19. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Cryst. 1993, 26:283-291.
20. Liang T.J., Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 2004, 127:62-71.
21. Lin K. Development of novel antiviral therapies for hepatitis C virus. Virol. Sin. 2010, 25:246-266.
22. Ma Y., Yates J., Liang Y., Lemon S.M., Yi M. NS3 helicase domains involved in infectious intracellular hepatitis C virus particle assembly. J. Virol. 2008, 82(15):7624-7639.
23. Mousseau G., Kota S., Takahashi V., Frick D.N., Strosberg A.D. Dimerization-driven interaction of hepatitis C virus core protein with NS3 helicase. J. Gen. Virol. 2011, 92(1):101-111.
24. Penin F. Structural biology of hepatitis C virus. Clin. Liver Dis. 2003, 7:1-21.
25. Phoon C.W., Ng P.Y., Ting A.E., Yeo S.L., Sim M.M. Biological evalution of hepatitis c virus inhibitors. Bioorg. Med. Chem. Lett. 2001, 11:1647-1650.
26. Poungpair O., Pootong A., Maneewatch S., Srimanote P., Tongtawe P., Songserm T., Tapchaisri P., Chaicumpa W. A human single chain transbody specific to matrix protein (M1) interferes with the replication of influenza A virus. Bioconjug. Chem. 2010, 21:1134-1141.
27. Smith S.M., Wunder M.B., Norris D.A., Shellman Y.G. A simple protocol for using a LDH-based cytotoxicity assay to assess the effects of death and growth inhibition at the same time. PLoS ONE 2011, 6(11):e26908. 10.1371/journal.pone.0026908.
28. Tai C.L., Chi W.K., Chen D.S., Hwang L.H. The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3). J. Virol. 1996, 70:8477-8484.
29. HH that neutralizes the zinc metalloproteinase activity of botulinum neurotoxin type A. J. Biol. Chem. 2010, 285:9657-9666.
30. HH that inhibit RNA dependent RNA polymerase (NS5B) of HCV. PLoS ONE 2012, 7:e49254.
31. Tsubota A., Fujise K., Namiki Y., Tada N. Peginterferon and ribavirin treatment for hepatitis C virus infection. World J. Gastroenterol. 2011, 17:419-432.
32. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Krausslich H.G., Mizokami M., Bartenschlager R., Liang T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11:791-796.
33. Wei W., Cai C., Kota S., Takahashi V., Ni F., Strosberg A.D., Snyder J.K. New small molecule inhibitors of hepatitis C virus. Bioorg. Med. Chem. Lett. 2009, 19:6926-6930.
34. Yao N., Webber P.C. Helicase, a target for novel inhibitors of hepatitis C virus. Antivir. Ther. 1998, 3:93-97.
35. You L.R., Chen C.M., Yeh T.S., Tsai T.Y., Mai R.T., Lin C.H., Lee Y.H. Hepatitis C virus core protein interacts with cellular putative RNA helicase. J. Virol. 1999, 73:2841-2853.
36. Yu C.I., Chiang B.L. A new insight into hepatitis C vaccine development. J. Biomed. Biotechnol. 2010, 2010:548280.